707 related articles for article (PubMed ID: 29625593)
1. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
2. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial.
Huang JF; Zhang FZ; Zou QZ; Zhou LY; Yang B; Chu JJ; Yu JH; Zhang HW; Yuan XP; Tai GM; Liu FJ; Ma CC
Oncotarget; 2017 Jan; 8(2):2457-2465. PubMed ID: 27974693
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
5. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
Lv JW; Li JY; Luo LN; Wang ZX; Chen YP
J Immunother Cancer; 2019 Jun; 7(1):159. PubMed ID: 31238988
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.
Makowska A; Lelabi N; Nothbaum C; Shen L; Busson P; Tran TTB; Eble M; Kontny U
Cells; 2021 Sep; 10(9):. PubMed ID: 34572108
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
[TBL] [Abstract][Full Text] [Related]
8. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
Carausu M; Beddok A; Langer A; Girard N; Bidard FC; Massiani MA; Ricard D; Cabel L
J Immunother Cancer; 2019 Nov; 7(1):317. PubMed ID: 31753021
[TBL] [Abstract][Full Text] [Related]
9. Current management of stage IV nasopharyngeal carcinoma without distant metastasis.
Ng WT; Corry J; Langendijk JA; Lee AWM; Mäkitie A; Mendenhall WM; Rinaldo A; Rodrigo JP; Saba NF; Smee R; Strojan P; Suárez C; Vermorken JB; Ferlito A
Cancer Treat Rev; 2020 Apr; 85():101995. PubMed ID: 32113080
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
Li D; He C; Xia Y; Du Y; Zhang J
J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
[TBL] [Abstract][Full Text] [Related]
11. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
13. Salvage Endoscopic Skull Base Surgery: Another Treatment Option After Immunotherapy for Recurrent Nasopharyngeal Carcinoma.
Peng Z; Wang Y; Fang Y; Wang Y; Yuan X; Shuai M; Xie S; Fan R; Zhang H; Xie Z; Jiang W
Front Immunol; 2022; 13():899932. PubMed ID: 35686123
[TBL] [Abstract][Full Text] [Related]
14. Image-based diagnosis of residual or recurrent nasopharyngeal carcinoma may be a phantom tumor phenomenon.
Lee CC; Lee JC; Huang WY; Juan CJ; Jen YM; Lin LF
Medicine (Baltimore); 2021 Feb; 100(8):e24555. PubMed ID: 33663063
[TBL] [Abstract][Full Text] [Related]
15. Prolonged complete remission after induction chemotherapy followed by chemoradiation with tomotherapy in metastatic nasopharyngeal cancer.
Agnese D; Belgioia L; Bacigalupo A; Marcenaro M; Vecchio S; Agostinelli S; Morbelli S; Corvò R
Anticancer Res; 2014 Sep; 34(9):5075-8. PubMed ID: 25202093
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.
Hua YJ; Han F; Lu LX; Mai HQ; Guo X; Hong MH; Lu TX; Zhao C
Eur J Cancer; 2012 Dec; 48(18):3422-8. PubMed ID: 22835782
[TBL] [Abstract][Full Text] [Related]
17. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
[TBL] [Abstract][Full Text] [Related]
18. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
19. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
[TBL] [Abstract][Full Text] [Related]
20. Spatiotemporal homogeneity and distinctness of the T-cell receptor β-chain repertoires in Epstein-Barr virus-associated primary and metastatic nasopharyngeal carcinomas.
Chung YL; Wu ML
Int J Cancer; 2018 Aug; 143(3):610-620. PubMed ID: 29468660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
